PKTX - ProtoKinetix and IQVIA partner to support development of eye treatment

Clinical-stage biomedical company ProtoKinetix (PKTX) and IQVIA (IQV) enter into a collaboration to accelerate the development of AAGP (PKX-001) in ocular conditions, specifically dry eye disease and wet and dry forms of age-related macular degeneration.The collaboration is expected to drive directed clinical development as PKX-001 enters Phase 1 testing.The initiative will also serve to optimize clinical trials to determine safety in these new conditions, drawing from previous experience with PKX-001 in Type 1 diabetes and other conditions, the companies said.

For further details see:

ProtoKinetix and IQVIA partner to support development of eye treatment